Silver Book Fact

One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.

Holloway, Robert G. et al. Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-year randomized controlled trial. Arch Neurol. 2004; 61(7): 1044-53. http://archneur.ama-assn.org/cgi/content/full/61/7/1044

Reference

Title
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-year randomized controlled trial
Publication
Arch Neurol
Publication Date
2004
Authors
Holloway, Robert G. et al.
Volume & Issue
Volume 61, Issue 7
Pages
1044-53
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, every $1 spent on Alzheimer’s research would save Medicare $10 by 2015 and $25 by 2025.  
  • Impact of Slowed Progression on Alzheimer’s Disease Growth, Americans Age 65 and Older with Alzheimer’s, 2010-2050  
  • Out-of-Pocket Costs, 5-Year Delayed Onset  
  • More Effective Treatment of Alzheimer’s Disease Could Save Billions: Combined Medicare and Medicaid savings from effective treatment of Alzheimer’s diease  
  • Recent studies suggest that a low-fat diet which is rich in fruits and vegetables may support brain health. Other studies suggest that remaining socially active and intellectually engaged may also…